The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema (NCT06075147) — France Trial Details

Condition(s) studied

Visual ImpairmentNeovascular Age-related Macular Degeneration (nAMD)Diabetic Macula Edema (DME)

Investigational drug(s) / intervention(s)

Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321) →

Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321): Following the manner of observational study, no intervention will be provided in the study. Any treatment decision, including the decision for aflibercept 8 mg treatment, is at the discretion of the attending physician, made in accordance with his/her experience and follows approved clinical guidelines.

Study summary

This is an observational study in which only data are collected from people who have already been prescribed aflibercept 8 mg by their own doctors.

In this study, data from adults with visual impairment due to neovascular age-related macular degeneration (nAMD) or diabetic macula edema (DME) will be collected and studied.

Visual impairment is any degree of vision loss that affects a person's ability to perform daily activities. nAMD is an eye disorder that causes vision loss due to the growth of abnormal blood vessels that leak blood or retinal fluid into the macula (the central part of the retina). nAMD is a leading cause of vision loss for people aged 50 and older. DME is a diabetes-related eye disorder. In DME, the macula swells up due to fluid leakage from damaged blood vessels, resulting in vision problems.

Aflibercept 8 mg is a drug that is injected into the eye. It works by blocking a protein called vascular endothelial growth factor (VEGF) which causes abnormal growth and leakage of blood vessels at the back of the eye.

Aflibercept 8 mg has been submitted for approval for the treatment of visual impairment due to nAMD and DME based on the results from 2 studies called PHOTON and PULSAR. This study will begin once approval is obtained. Currently, no real-world data are available for aflibercept 8 mg.

The main purpose of this study is to collect more information about how well aflibercept 8 mg injection works in people with nAMD and DME. This study will include participants who have not received any prior treatment for nAMD or DME and participants who have.

The main information that researchers will collect:

the change in vision test scores called the best corrected visual acuity (BCVA) after 12 months of treatment.

Data will be collected from February 2024 to September 2027 and will cover a period of up to 24 months per participant. The data will be collected using medical records and by interviewing the patients during regular visits that take place in routine practice.

Researchers will observe participants from the first injection of aflibercept 8 mg until the end of the observation.

In this study, only available data from regular visits will be collected. No visits or tests are required as part of this study.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

No

Inclusion Criteria: Inclusion criteria for patients with nAMD * A diagnosis of nAMD * Patient aged ≥50 years * Patients for whom the decision to initiate treatment with intravitreal (IVT) aflibercept 8 mg according to a local product information was made as part of routine clinical practice * Signed informed patient consent before the start of data collection (according to the requirements of the local authorities and laws) Inclusion criteria for patients with DME * A diagnosis of DME * Patient aged ≥18 years (or country's legal age of adulthood if the legal age is \>18 years) with type 1 or type 2 diabetes mellitus * Patients for whom the decision to initiate treatment with IVT aflibercept 8 mg according to a local product information was made as part of routine clinical practice * Signed informed patient consent before the start of data collection (according to the requirements of the local authorities and laws) Exclusion Criteria: Exclusion criteria for all patients with nAMD * Participation in an investigational program with interventions outside of clinical routine practice * Contraindications as listed in the local intravitreal aflibercept 8 mg local product information * Extra/periocular infection or inflammation in either eye at time of first injection * Patient receiving other intravitreal treatments other than aflibercept in the fellow eye * Any medication interfering with aflibercept 8 mg in the intravitreal aflibercept 8 mg local product information Additional exclusion criteria for treatment-naïve patients with nAMD * Any prior ocular treatment in the study eye or systemic treatment in nAMD Additional exclusion criteria for pretreated patients with nAMD * Prior intravitreal anti-VEGF treatments in the study eye within the last 28 days * Prior treatment with intravitreal corticosteroid in the study eye within the last 3 months * Fluocinolone implant in the study eye within the last 3 years * Dexamethasone implant in the study eye within the last 6 months * Any concurrent drug releasing implant in the study eye Exclusion criteria for all patients with DME * Participation in an investigational program with interventions outside of clinical routine practice * Contraindications as listed in the intravitreal aflibercept 8 mg local product information * Extra/periocular infection or inflammation in either eye at time of first injection * Patient receiving other intravitreal treatments other than aflibercept in the fellow eye * Any medication interfering with aflibercept 8 mg in the intravitreal aflibercept 8 mg local product information * Previous treatment of the study eye with laser in the last 90 days prior to first IVT aflibercept 8 mg Additional exclusion criteria for treatment-naïve patients with DME * Any prior ocular treatment in the study eye or systemic treatment in DME Additional exclusion criteria for pretreated patients with DME * Prior intravitreal anti-VEGF treatments in the study eye within the last 28 days * Prior treatment with intravitreal corticosteroid in the study eye within the last 3 months * Fluocinolone implant in the study eye within the last 3 years * Dexamethasone implant in the study eye within the last 6 months * Any concurrent drug releasing implant in the study eye

Primary outcome measure(s)

The change of best corrected visual acuity (BCVA) from baseline to 12 months as evaluated in routine clinical practice — At baseline and 12 months
BCVA measurements at baseline (first injection of aflibercept 8 mg) and at 12 months as ETDRS letters (according to the Early Treatment Diabetic Retinopathy Study (ETDRS) chart or other methods (e.g. Snellen charts) used in the routine clinical practice in participating countries or sites (with conversion to ETDRS))

Trial sites (18)

Facility	City	Region
Many Locations	Multiple Locations	Australia
Many Locations	Multiple Locations	Canada
Many Locations	Multiple Locations	Denmark
Many Locations	Multiple Locations	Finland
Many Locations	Multiple Locations	France
Many Locations	Multiple Locations	Germany
Many Locations	Multiple Locations	Italy
Many Locations	Multiple Locations	Japan
Many Locations	Multiple Locations	Netherlands
Many Locations	Multiple Locations	Norway
Many Locations	Multiple Locations	Portugal
Many Locations	Multiple Locations	Saudi Arabia
Many Locations	Multiple Locations	South Korea
Many Locations	Multiple Locations	Spain
Many Locations	Multiple Locations	Sweden
Many Locations	Multiple Locations	Switzerland
Many Locations	Multiple Locations	United Arab Emirates
Many Locations	Multiple Locations	United Kingdom

More Bayer trials in France

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer) Active, not recruiting

A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described Active, not recruiting

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria Active, not recruiting

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) Recruiting

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria Recruiting

Other trials for the same condition

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration Active, not recruiting

A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) Active, not recruiting

Touching the World With a Cane: Cognitive and Neural Processes Recruiting